According to the 2019 Infectious Diseases Society of America (IDSA) guidelines, routine screening for or treatment of asymptomatic bacteriuria (ASB) before elective nonurologic surgery, including cardiothoracic surgery, is not recommended (strong recommendation, low-quality evidence). This recommendation was informed by three studies involving 3,167 surgical patients, including patients undergoing cardiac and vascular procedures, of whom 403 (12.7%) had ASB. Approximately 47% of patients with ASB received targeted antimicrobial treatment in addition to perioperative prophylaxis. The guideline concluded that the benefit of treating ASB beyond standard perioperative prophylaxis remains highly uncertain, with very low certainty regarding effects on postoperative infectious outcomes. Additionally, evidence is insufficient to determine whether expanding perioperative prophylaxis to cover urinary pathogens provides additional benefit. The guideline does not specifically evaluate whether ASB screening or treatment reduces future infective endocarditis. [1]
According to the 2026 European Association of Urology (EAU) guidelines, screening for or treating ASB before cardiovascular surgery is not recommended (strong recommendation). This recommendation is supported by a 2018 systematic review and meta-analysis of three retrospective, nonrandomized studies involving 1,116 patients undergoing nonvalvular coronary artery bypass grafting (n= 473; 42%), valve replacement (n= 567; 51%), or thoracic aortic surgery (n= 76; 7%). Of these patients, 116 received targeted antimicrobial treatment for ASB before surgery. Surgical-site infections occurred more frequently among treated patients than untreated patients (12.9% vs 8.2%), although the difference was not statistically significant (p= 0.086). Similarly, the random-effects meta-analysis found no statistically significant reduction in infectious complications with ASB treatment (odds ratio [OR] 1.38; 95% confidence interval [CI] 0.56 to 3.38), with moderate heterogeneity across studies (I²= 64%). The guidelines acknowledge that the small number of studies, retrospective and nonrandomized designs, and heterogeneity limit the certainty of these findings. Importantly, the guidelines and the analysis did not specifically evaluate infective endocarditis as an outcome, and evidence demonstrating that preoperative ASB screening or treatment reduces the risk of future infective endocarditis is lacking. [2], [3]